Serum magnesium deficiency and its metabolic-vascular correlates in adults with type 2 diabetes mellitus at a Nigerian Tertiary Hospital Authors: Tajudin Adesegun Adetunji, David Olubukunmi Soyoye, Muzamil Olamide Hassan, Oluwasegun Ijarotimi, Gbenga Joshua Odunlami, Ummulkhair Funke Adetunji, Okechukwu Obumneme Ezekpo, Yetunde Akuma, Adetokunbo Ajala, Babatope Ayodeji Kolawole, Rosemary Temidayo Ikem Published: 2026 ABSTRACT ObjectivesTo compare serum magnesium levels between patients with type 2 diabetes mellitus (T2DM) and age- and sex-matched non-diabetic controls, and evaluate the relationship between serum magnesium, β-cell function, glycaemic control, nephropathy, and peripheral arterial disease (PAD).ResultsIn this hospital-based cross-sectional study, 83 patients with T2DM and 83 matched controls were evaluated. Serum magnesium was measured using inductively coupled plasma-optical emission spectrometry, while β-cell function and insulin resistance were assessed using the HOMA2 model. Nephropathy was assessed by albumin-creatinine ratio, and PAD by ankle-brachial index. Median serum magnesium levels were significantly lower in patients with T2DM than in controls [0.40 (0.30–0.43) vs. 0.88 (0.76–1.02) mmol/L, p < 0.001]. Hypomagnesaemia was present in all diabetic participants. Serum magnesium correlated positively with HOMA2-%β (rho = 0.47, p = 0.002), fasting insulin (rho = 0.42, p = 0.003), and HOMA2-IR (rho = 0.43, p = 0.004), but not HbA1c (rho = − 0.13, p = 0.21). Patients with microalbuminuria had significantly lower β-cell function indices (p = 0.002), while serum magnesium showed no significant association with albuminuria or PAD. These findings suggest that hypomagnesaemia is prevalent among Nigerian patients with T2DM and may reflect impaired β-cell function rather than established vascular complications.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13104-026-07901-8. Introduction Type 2 diabetes mellitus (T2DM) is a growing global health concern, characterised by chronic hyperglycaemia resulting from insulin resistance and/or inadequate insulin secretion. It accounts for over 90% of all diabetes cases and disproportionately affects populations in low- and middle-income countries, particularly in sub-Saharan Africa, where urbanisation, changing dietary habits, and limited access to care exacerbate its burden [1–3]. In Nigeria, the prevalence of T2DM has risen significantly in recent decades, with an estimated 4.7 million adults affected, many of whom remain undiagnosed [4]. Beyond its metabolic derangements, T2DM is associated with both microvascular and macrovascular complications, including nephropathy, retinopathy, and peripheral arterial disease (PAD), which significantly increase morbidity and mortality [5–7]. Therefore, identifying modifiable factors that influence these complications remains a key public health and clinical priority. Magnesium (Mg), the second most abundant intracellular divalent cation, is essential for numerous physiological processes, including glucose transport, insulin secretion, and cellular energy metabolism. It functions as a cofactor for more than 300 enzymatic reactions, particularly those involved in carbohydrate metabolism and insulin receptor signalling [8–10]. In healthy individuals, magnesium homeostasis is tightly regulated through intestinal absorption and renal excretion. However, in individuals with diabetes, hyperglycaemia-induced osmotic diuresis and insulin resistance may disrupt this balance, resulting in magnesium loss and subsequent hypomagnesaemia [11–13]. Hypomagnesaemia has been reported in 13.5–47.7% of patients with T2DM globally [14], with African studies suggesting similar or higher prevalence rates [15, 16]. Mechanistic evidence suggests that magnesium deficiency impairs insulin receptor phosphorylation and tyrosine kinase activity, thereby worsening insulin resistance and glycaemic control [17]. Furthermore, low serum magnesium levels have been associated with increased systemic inflammation, endothelial dysfunction, and vascular complications such as hypertension and atherosclerosis [18–20]. Clinical trials and observational studies have also demonstrated that magnesium supplementation may improve insulin sensitivity and β-cell function and slow the progression of diabetic complications [21–23]. Despite this evidence, the clinical significance of magnesium deficiency in African populations with T2DM remains poorly elucidated. In particular, the relationship between serum magnesium and diabetic complications such as nephropathy and PAD has not been adequately explored in Nigerian cohorts. This knowledge gap hinders the potential use of serum magnesium as a simple, cost-effective biomarker for early risk stratification. The study aimed to compare serum magnesium levels in Nigerian adults with T2DM and matched controls, and to assess their relationship with glycaemic control, β-cell function, insulin resistance, nephropathy, and PAD. Methods Study design and setting This descriptive, hospital-based cross-sectional study was conducted at the Diabetes Clinic of Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, southwest Nigeria. Study population and sample size determination The study involved 166 adults aged 30 to 70 years: 83 patients with T2DM and 83 age- and sex-matched non-diabetic controls. Sample size was estimated for a two-group comparison of means at 95% confidence level and 80% power, using an effect size of 0.05 and a pooled SD of 0.1095 [24] and increased to 83 per group to allow for attrition. T2DM was diagnosed using the WHO criteria [25]. Eligible patients had diabetes for at least one year and were on regular follow-up. Participants with conditions or medications affecting magnesium metabolism, including overt renal failure, malignancy, pregnancy, loop diuretics, or magnesium/calcium supplementation, were excluded. Controls were recruited from hospital staff and the community after screening for diabetes and other chronic diseases. Sampling technique A systematic random sampling method was used, with every third eligible consenting subject recruited consecutively from the Clinic until the required sample size was reached. Ethical approval Ethical approval was obtained from the institutional Ethics and Research Committee (IRB/IEC/0004553, 26/02/2018), and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki [26]. Data collection Demographic and clinical data were collected using a structured proforma (Supplementary file 1), while anthropometric measurements included weight, height, BMI, waist circumference, and blood pressure recorded after rest using standard techniques. Biochemical analysis Fasting venous blood and early morning urine samples were collected for the measurement of serum magnesium, fasting plasma glucose, serum creatinine, insulin, and albumin-creatinine ratio (ACR). Serum magnesium Serum magnesium was measured using ICP-OES (PerkinElmer Optima 8000, USA). Values below 0.66 mmol/L were classified as hypomagnesaemia (reference range: 0.66–1.07 mmol/L) [27], and the assay showed intra- and inter-assay coefficient of variation (CVs) of 0.2% and 0.4%, respectively. Fasting capillary blood glucose Control participants were screened for undiagnosed diabetes using capillary fasting glucose measured with the Accu-Chek® Active glucometer, which uses the glucose–dye–oxidoreductase mediator reaction; values of ≤ 6.1 mmol/L were considered eligible, and the screening results were not included in the analysis. Fasting plasma glucose Fasting glucose in cases was measured from venous blood using the glucose oxidase–peroxidase method with AGAPE kits (Switzerland), with intra- and inter-assay CVs of 2.2% and 3.2%, respectively. Glycated haemoglobin (HbA1c) HbA1c was measured using the ichromax® fluorescent immunoassay method (Boditech Med Inc., Republic of Korea) according to the manufacturer’s instructions, and values below 7% were considered good glycaemic control [28]. Fasting serum insulin Fasting serum insulin was measured in duplicate by Enzyme-linked immunosorbent assay (ELISA, Monobind Inc., USA) on the Chemwell 2910 autoanalyser; the reference range for normal adults was 0.7–9.0 µIU/ml, while the range for adults with type 2 diabetes mellitus was 0.7–25 µIU/ml. The assay had a sensitivity of 0.182 µIU/ml, no cross-reactivity with C-peptide, proinsulin, or glucagon, and intra- and inter-assay CVs of 6.2% and 7.0%, respectively. Serum and urine creatinine The analytes were measured using the modified Jaffe reaction with an Agappe Diagnostic kit (Switzerland), with intra- and inter-assay CVs of 4.7% and 7.3%, respectively. Urinary albumin Urinary albumin was measured by sandwich immunodetection using ichromax® (Boditech Med Inc., Republic of Korea), with intra- and inter-assay CVs of 4.3% and 6.6%, respectively. ACR was calculated, and the estimated glomerular filtration rate (eGFR) was derived using the Chronic Kidney Disease Epidemiology Collaboration (CKD – EPI) equation to assess nephropathy [29]. Assessment of β-cell function and insulin resistance β-cell function and insulin resistance were calculated using the HOMA2 model, a validated tool that adjusts for hepatic and peripheral glucose dynamics. Outputs included: HOMA2-%β (β-cell function) and HOMA2-IR (insulin resistance) [30]. Peripheral arterial disease (PAD) evaluation This was assessed using the Ankle–Brachial Index (ABI)—the ratio of ankle to brachial systolic pressure—measured using an 8-MHz handheld Doppler device (LifeDop®, Summit Doppler). ABI < 0.90 was considered diagnostic of PAD [31]. Statistical analysis Data were analysed using IBM SPSS version 22.0. Continuous variables were tested for normality using the Kolmogorov–Smirnov test and presented as mean ± SD or median (interquartile range), as appropriate. Group comparisons were made using Student’s t-test or the Mann–Whitney U test for continuous variables, and the chi-square test or Fisher’s exact test for categorical variables. Associations were assessed using Spearman’s rank correlation (rho), with p < 0.05 considered statistically significant. Results We enrolled 83 adults with T2DM and 83 age- and sex-matched controls. The Results are presented in three parts: baseline characteristics, the relationship between magnesium and β-cell function, and glycaemic indices; and the distribution of microvascular (albuminuria) and macrovascular (PAD) complications across magnesium strata, with significance set at p < 0.05. Baseline characteristics Table 1 shows comparable age and sex distribution between groups, but significantly higher BMI, waist circumference, and systolic blood pressure in the T2DM group (p < 0.001). Table 1Baseline characteristics of study participantsVariableT2DM patients (n = 83)Controls (n = 83)p-valueAge (years), mean ± SD56.8 ± 9.255.9 ± 8.50.46Female sex, n (%)47 (56.6%)45 (54.2%)0.74BMI (kg/m²), mean ± SD28.6 ± 4.224.3 ± 3.9< 0.001*Waist circumference (cm)95.2 ± 9.183.6 ± 8.5< 0.001*Systolic BP (mmHg), mean ± SD138.4 ± 16.1122.5 ± 14.8< 0.001*Diastolic BP (mmHg), mean ± SD84.7 ± 9.479.6 ± 8.70.004*T2DM-Type 2 diabetes mellitus, BP-Blood Pressure, cm-centimetres, mmHg-millimetres of Mercury, SD - SD-standard deviation, *p-value- significant Table 1Baseline characteristics of study participantsVariableT2DM patients (n = 83)Controls (n = 83)p-valueAge (years), mean ± SD56.8 ± 9.255.9 ± 8.50.46Female sex, n (%)47 (56.6%)45 (54.2%)0.74BMI (kg/m²), mean ± SD28.6 ± 4.224.3 ± 3.9< 0.001*Waist circumference (cm)95.2 ± 9.183.6 ± 8.5< 0.001*Systolic BP (mmHg), mean ± SD138.4 ± 16.1122.5 ± 14.8< 0.001*Diastolic BP (mmHg), mean ± SD84.7 ± 9.479.6 ± 8.70.004*T2DM-Type 2 diabetes mellitus, BP-Blood Pressure, cm-centimetres, mmHg-millimetres of Mercury, SD - SD-standard deviation, *p-value- significant Baseline characteristics of study participants T2DM-Type 2 diabetes mellitus, BP-Blood Pressure, cm-centimetres, mmHg-millimetres of Mercury, SD - SD-standard deviation, *p-value- significant Serum magnesium and glycaemic status Table 2 shows significantly lower serum magnesium in T2DM participants than controls, with hypomagnesaemia present in all diabetic participants but in only 3.6% of controls; magnesium levels did not differ significantly by glycaemic control among diabetic participants (p = 0.58). Table 2Serum magnesium, Glycaemic indices, and insulin measuresParameterT2DM patientsControlsp-valueSerum Mg (mmol/L), median (IQR)0.40 (0.30–0.43)0.88 (0.76–1.02)< 0.001*Hypomagnesaemia prevalence (%)100%3.6%< 0.001*Fasting insulin (µIU/mL), median (IQR)9.8 (5.2–14.7)15.3 (12.1–18.6)< 0.001*HOMA2-%β, median (IQR)46.2 (31.8–61.4)88.5 (71.4–109.2)< 0.001*HOMA2-IR, median (IQR)2.5 (1.6–3.8)1.2 (0.9–1.6)< 0.001*HbA1c (%), mean ± SD8.1 ± 1.4——T2DM -Type 2 diabetes mellitus, Mg – Magnesium, HOMA-IR -Homeostasis Model Assessment of Insulin Resistance, IQR- Interquartile Range, SD- Standard deviation, *p-value- significant. (Reference range for Serum Mg: 0.66–1.07 mmol/l) Table 2Serum magnesium, Glycaemic indices, and insulin measuresParameterT2DM patientsControlsp-valueSerum Mg (mmol/L), median (IQR)0.40 (0.30–0.43)0.88 (0.76–1.02)< 0.001*Hypomagnesaemia prevalence (%)100%3.6%< 0.001*Fasting insulin (µIU/mL), median (IQR)9.8 (5.2–14.7)15.3 (12.1–18.6)< 0.001*HOMA2-%β, median (IQR)46.2 (31.8–61.4)88.5 (71.4–109.2)< 0.001*HOMA2-IR, median (IQR)2.5 (1.6–3.8)1.2 (0.9–1.6)< 0.001*HbA1c (%), mean ± SD8.1 ± 1.4——T2DM -Type 2 diabetes mellitus, Mg – Magnesium, HOMA-IR -Homeostasis Model Assessment of Insulin Resistance, IQR- Interquartile Range, SD- Standard deviation, *p-value- significant. (Reference range for Serum Mg: 0.66–1.07 mmol/l) Serum magnesium, Glycaemic indices, and insulin measures T2DM -Type 2 diabetes mellitus, Mg – Magnesium, HOMA-IR -Homeostasis Model Assessment of Insulin Resistance, IQR- Interquartile Range, SD- Standard deviation, *p-value- significant. (Reference range for Serum Mg: 0.66–1.07 mmol/l) Association between serum magnesium and pancreatic function indices There was a statistically significant positive correlation between serum magnesium and fasting insulin levels (rho = 0.42, p = 0.003), HOMA2-%β (rho = 0.47, p = 0.002), and HOMA2-IR (rho = 0.43, p = 0.004). These findings, depicted in Table 3, suggest that lower magnesium levels may be associated with reduced pancreatic β-cell function and altered insulin resistance profiles. Table 3Correlation between serum magnesium and key metabolic and vascular parameters in the T2DM groupParameterCorrelation coefficient (rho)p-valueFasting insulin(µIU/mL)0.420.003*HOMA2-%β0.470.002*HOMA2-IR0.430.004*HbA1c (%)–0.130.21Urinary ACR (mg/g)–0.160.18eGFR(ml/min/1.73m2)–0.020.89Ankle–Brachial Index (ABI)0.090.32ACR - Albumin Creatinine Ratio; eGFR - estimated Glomerular Filtration Rate; HbA1c – Glycated Haemoglobin; HOMA-IR - Homeostasis Model Assessment of Insulin Resistance; IQR- Interquartile Range, SD - Standard deviation;, *p-value- significant Table 3Correlation between serum magnesium and key metabolic and vascular parameters in the T2DM groupParameterCorrelation coefficient (rho)p-valueFasting insulin(µIU/mL)0.420.003*HOMA2-%β0.470.002*HOMA2-IR0.430.004*HbA1c (%)–0.130.21Urinary ACR (mg/g)–0.160.18eGFR(ml/min/1.73m2)–0.020.89Ankle–Brachial Index (ABI)0.090.32ACR - Albumin Creatinine Ratio; eGFR - estimated Glomerular Filtration Rate; HbA1c – Glycated Haemoglobin; HOMA-IR - Homeostasis Model Assessment of Insulin Resistance; IQR- Interquartile Range, SD - Standard deviation;, *p-value- significant Correlation between serum magnesium and key metabolic and vascular parameters in the T2DM group ACR - Albumin Creatinine Ratio; eGFR - estimated Glomerular Filtration Rate; HbA1c – Glycated Haemoglobin; HOMA-IR - Homeostasis Model Assessment of Insulin Resistance; IQR- Interquartile Range, SD - Standard deviation;, *p-value- significant Serum magnesium, β-cell function and microvascular complications among the T2DM group The median levels of ACR and eGFR were 27(9.68–79.18) mg/g, 74.80 (59.35–92.63) ml/min/1.73m2, respectively. Figure 1 shows the prevalence of albuminuria among the diabetic participants. Among patients with T2DM, those with microalbuminuria (ACR 30–300 mg/g) had significantly lower β-cell function (mean HOMA2-%β) compared to those with normal ACR (p = 0.002). However, serum magnesium levels were not significantly different between diabetic participants with and without microalbuminuria (p = 0.08). Fig. 1Distribution of albuminuria among diabetic participants Distribution of albuminuria among diabetic participants Serum magnesium and macrovascular complications among the T2DM group The median ABI values were similar in both feet and across genders. Most participants had normal ABI values in the right (71.1%) and left (68.4%) feet, although PAD-suggestive ABI values were slightly more frequent in the left than the right foot (31.6% vs. 27.6%). Extreme ABI values were observed in 15.8% of the right feet and 13.2% of the left feet. Similarly, the prevalence of PAD (ABI < 0.90) did not differ significantly based on serum magnesium status (p = 0.21). As shown in Table 4, no correlation was found between magnesium and ABI values. Table 4Correlation between serum magnesium and ankle brachial indices of each foot across genderVariableSpearman’s Rhop-valueABI Right Foot0.1780.125ABI Right Foot (Male)0.1700.461ABI Right Foot (Female)0.1940.157ABI Left Foot0.1360.241ABI Left Foot (Male)0.1490.518ABI Left Foot (Female)0.1250.363ABI-Ankle Brachial Index; Rho- Correlation coefficient Table 4Correlation between serum magnesium and ankle brachial indices of each foot across genderVariableSpearman’s Rhop-valueABI Right Foot0.1780.125ABI Right Foot (Male)0.1700.461ABI Right Foot (Female)0.1940.157ABI Left Foot0.1360.241ABI Left Foot (Male)0.1490.518ABI Left Foot (Female)0.1250.363ABI-Ankle Brachial Index; Rho- Correlation coefficient Correlation between serum magnesium and ankle brachial indices of each foot across gender ABI-Ankle Brachial Index; Rho- Correlation coefficient Discussion This study revealed a high prevalence of hypomagnesaemia (100%) among Nigerian patients with type 2 diabetes mellitus (T2DM), higher but consistent with earlier reports indicating a strong relationship between T2DM and magnesium deficiency [14–16]. Median serum magnesium levels were significantly lower in diabetic patients compared to controls, supporting the hypothesis that altered magnesium metabolism is a common feature of T2DM and may reflect or contribute to the metabolic derangements seen in these individuals. Odusan et al. (2017) similarly reported significantly lower mean serum magnesium levels in Nigerian patients with T2DM compared to healthy controls, with hypomagnesaemia observed in over half of their study population. They also demonstrated that low serum magnesium was more prevalent in those with poor glycaemic control, hypertension, and longer diabetes duration, suggesting a link between magnesium deficiency and adverse metabolic and cardiovascular profiles [32]. In agreement, Nsonwu et al. found that diabetic subjects in Calabar, Nigeria, had significantly reduced serum magnesium levels compared to non-diabetic controls, and that magnesium concentrations were inversely correlated with fasting plasma glucose and glycated haemoglobin [33]. Their findings reinforce the concept that hypomagnesaemia in T2DM is not merely an incidental finding but is closely tied to the degree of glycaemic dysregulation, possibly via impaired insulin secretion, increased urinary magnesium loss, and enhanced oxidative stress. Similar trends have been observed across sub-Saharan Africa, with studies in Ghana and Ethiopia reporting hypomagnesaemia prevalence rates between 45% and 70% among T2DM patients, often in association with poor glycaemic control and higher rates of microvascular complications [34, 35]. Globally, large-scale observational studies and meta-analyses have confirmed that individuals with lower serum magnesium levels are at increased risk of both developing T2DM and experiencing its complications. Song et al. [2013], in a meta-analysis of prospective cohort studies, reported that higher dietary and serum magnesium were associated with a significantly reduced risk of T2DM [36]. Furthermore, Guerrero-Romero and Rodríguez-Morán [2011] highlighted that magnesium supplementation in T2DM patients improved insulin sensitivity and metabolic control, underscoring the potential clinical relevance of identifying and correcting hypomagnesaemia in routine diabetes care [37]. The positive correlation observed between serum magnesium and β-cell function (HOMA2-%β) suggests a functional relationship between magnesium status and insulin secretory capacity. This finding corroborates previous studies demonstrating that magnesium plays a critical role in insulin biosynthesis and secretion [8, 17, 18]. Mechanistically, magnesium is required for ATP formation, which is vital for glucose-stimulated insulin exocytosis. Additionally, magnesium acts as a cofactor in tyrosine kinase activity at the insulin receptor level, influencing downstream signalling [9, 17]. Magnesium deficiency may therefore contribute to progressive β-cell failure, a hallmark of T2DM pathogenesis. Although we found a significant association between serum magnesium and insulin resistance (HOMA2-IR), the relationship was not linear, and the correlation strength was moderate. This aligns with findings from Rodríguez-Morán et al. [2003], who reported improved insulin sensitivity following oral magnesium supplementation in non-diabetic insulin-resistant individuals [21]. However, the directionality of causation remains unclear—whether magnesium deficiency promotes insulin resistance or results from it due to increased urinary excretion from hyperglycaemia-induced osmotic diuresis [13, 38]. Prospective studies are required to elucidate this bidirectional relationship. Contrary to expectations, serum magnesium levels were not significantly associated with HbA1c, a marker of long-term glycaemic control. This finding is consistent with results from Dasgupta et al. [39], but contrasts with findings of Luo et al., who reported inverse relationships and reduced odds of glycaemic control with hypomagnesemia in a large observational study of diabetic patients [40]. The lack of association may be attributable to confounding factors such as varying dietary intake, renal magnesium handling, and duration of diabetes. It also suggests that while magnesium may influence insulin physiology, it does not directly reflect cumulative glycaemic exposure. The lack of a statistically significant relationship between magnesium levels and peripheral arterial disease (PAD), as assessed by ABI, diverges from findings in Western populations where hypomagnesaemia has been associated with endothelial dysfunction and increased arterial stiffness [18, 41]. Discrepancy may reflect population differences in dietary patterns, disease duration, comorbidities, or methodological variability in PAD assessment. Nevertheless, magnesium’s established role in vascular tone regulation and endothelial stability warrants further investigation in African cohorts. Similarly, although patients with microalbuminuria had reduced β-cell function, serum magnesium did not differ significantly between those with and without nephropathy. This is at odds with several studies that reported lower magnesium in patients with diabetic nephropathy [19, 42]. It is possible that the absence of significant renal impairment in most diabetic participants may not yet have exerted a strong influence on systemic magnesium concentrations, especially in the absence of overt proteinuria or a significantly reduced glomerular filtration rate. Taken together, these findings highlight the potential of serum magnesium as a metabolic biomarker rather than a direct predictor of end-organ complications. Its association with insulin secretion and resistance suggests that magnesium status may serve as an early indicator of metabolic dysfunction before overt clinical deterioration. Study strengths and limitations A major strength of this study is its focus on a Nigerian population, contributing to the limited African literature on magnesium and diabetes. The inclusion of age- and sex-matched controls, use of ICP-OES for magnesium quantification, and application of HOMA2 for metabolic assessment enhance internal validity and more accurate detection of hypomagnesemia. However, certain limitations must be acknowledged. The cross-sectional design limits causal inference. Dietary magnesium intake and magnesium supplementation history were not assessed. ABI may underestimate PAD in individuals with vascular calcification. Additionally, residual confounders such as duration of diabetes, medications (e.g., metformin), and physical activity levels may have influenced results. Implications and future directions Given the high prevalence of hypomagnesaemia and its association with insulin secretory function, routine magnesium screening in patients with T2DM may offer a simple tool for early detection of β-cell dysfunction. Magnesium supplementation, if further validated in interventional trials, may provide an inexpensive adjunct in diabetes care, especially in resource-constrained settings. Future longitudinal and interventional studies are needed to clarify the causal relationship between magnesium status and β-cell function, determine if magnesium repletion alters disease trajectory, and explore its prognostic value in predicting microvascular complications. Conclusion This study demonstrated a high prevalence of hypomagnesaemia among Nigerian adults with type 2 diabetes mellitus, with significantly lower serum magnesium levels observed in diabetic patients compared to non-diabetic controls. Serum magnesium was positively associated with β-cell function and insulin resistance but showed no significant relationship with glycaemic control, nephropathy, or peripheral arterial disease. These findings underscore the potential role of magnesium as a surrogate marker of metabolic dysfunction rather than a direct indicator of vascular complications. Given its clinical relevance, routine magnesium assessment in diabetes care may offer added value in the early identification of β-cell dysfunction and insulin resistance. Further longitudinal studies and controlled trials are warranted to explore the therapeutic potential of magnesium supplementation in modifying the trajectory of type 2 diabetes and its complications, particularly in sub-Saharan African populations. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1.